术后分子残留病灶状态可细化食管鳞癌新辅助放化疗后的复发风险分层
分子残留病灶状态显著分层无复发生存和早期复发风险,1年复发率阴性组6.1%对阳性组66.7%(P < .001),多变量分析显示分子残留病灶阳性为独立预测因子(HR 13.62,P < .001),而病理反应不是。
要点
- 术后分子残留病灶状态显著分层复发风险,1年复发率6.1%对66.7%。
- 分子残留病灶阳性是独立预测因子(HR 13.62),病理反应不是。
- 联合病理完全缓解与分子残留病灶可分4个复发风险亚组。
核心结论
- 整合术后分子残留病灶与病理反应可改善复发风险分层,可能辅助辅助治疗决策,但需前瞻性验证。
研究设计与样本
- 术后3至4周采用肿瘤知情个性化循环肿瘤DNA检测判定分子残留病灶状态。
- 分析无复发生存和复发模式,中位随访36.5个月。
主要发现
- 病理完全缓解组1年复发率13.5%,非病理完全缓解组30.4%(P = .061)。
- 分子残留病灶阴性组1年复发率6.1%,阳性组66.7%(P < .001)。
- 多变量Cox回归显示分子残留病灶阳性是无复发生存的独立预测因子(HR 13.62,P < .001),病理反应不是。
- 联合分类识别4个风险亚组:病理完全缓解且分子残留病灶阴性1年复发率3.7%,非病理完全缓解且分子残留病灶阴性7.7%,病理完全缓解且分子残留病灶阳性40%,非病理完全缓解且分子残留病灶阳性82.4%(P < .001),分子残留病灶阳性组以远处复发为主。
临床怎么用
- 术后分子残留病灶检测可补充病理反应,细化复发风险分层。
- 分子残留病灶阳性患者早期复发风险高,或可考虑强化辅助治疗决策。
- 分子残留病灶阴性患者复发风险低,可能避免过度治疗。
局限性
- 分子残留病灶检测方法为肿瘤知情个性化循环肿瘤DNA assay,外推需考虑方法学差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Accurate postoperative recurrence-risk stratification is essential for adjuvant treatment decisions in esophageal cancer after neoadjuvant chemoradiotherapy. Pathologic complete response is widely used for risk assessment but shows limited discrimination. This study evaluated whether integrating postoperative molecular residual disease with pathologic response improves recurrence prediction. METHODS: This was a post hoc analysis of the preSINO trial. Patients with locally advanced esophageal squamous cell carcinoma who underwent neoadjuvant chemoradiotherapy followed by esophagectomy (2019-2023) and had molecular residual disease assessment were included. Molecular residual disease status was determined 3 to 4 weeks postsurgery using a tumor-informed personalized circulating tumor DNA assay. Recurrence-free survival and recurrence patterns were analyzed. RESULTS: Ninety-three patients were included, of whom 30 experienced recurrences during a median follow-up of 36.5 months. Most recurrences (73.3%) occurred within the first year postsurgery. A trend toward a lower 1-year recurrence rate was observed in patients with a pathologic complete response (13.5%) compared with patients without a pathologic complete response (30.4%) (P = .061). Molecular residual disease status significantly stratified recurrence-free survival and early recurrence risk, with 1-year recurrence rates of 6.1% versus 66.7% for molecular residual disease-negative versus molecular residual disease-positive groups (P < .001). Multivariable Cox-regression analysis demonstrated molecular residual disease positivity (hazard ratio, 13.62; P < .001) as an independent predictor of recurrence-free survival, whereas pathologic response was not. A classification combining pathologic complete response/non-pathologic complete response and molecular residual disease status identified 4 distinct recurrence risk subgroups: The 1-year recurrence rates were 3.7% of pathologic complete response and molecular residual disease negative, 7.7% of non-pathologic complete response and molecular residual disease negative, 40% of pathologic complete response and molecular residual disease positive, and 82.4% of non-pathologic complete response and molecular residual disease positive (P < .001), with distant recurrence predominating in molecular residual disease-positive groups. CONCLUSIONS: Integrating postoperative molecular residual disease with pathologic response improves recurrence risk stratification that may facilitate adjuvant therapy decisions but warrants prospective validation.
引用
- Liu Z, Yang Y, Yu B, et al. Postoperative molecular residual disease status refines recurrence risk stratification beyond pathologic response after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2026. PMID: 42086163. doi:10.1016/j.jtcvs.2026.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。